Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Diese Aktie meldet Mega-Deal: Nokia & Ericsson an Bord!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXP | ISIN: FR0012127173 | Ticker-Symbol: 6OP
Tradegate
15.09.25 | 16:00
5,980 Euro
+0,50 % +0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OSE IMMUNOTHERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
OSE IMMUNOTHERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,9006,05508:30
5,9305,98008:33

Aktuelle News zur OSE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln
FrOSE Immunotherapeutics: Update on Information Relating to the General Meeting of September 30, 20255
DoOSE Immunotherapeutics completes enrollment in lung cancer trial1
DoOSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer251OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with...
► Artikel lesen
09.09.OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 202545OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025 Nantes, September...
► Artikel lesen
08.09.OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders' Annual General Meeting of September 30, 20251
08.09.OSE Immunotherapeutics - executive interview221In this interview, Silvia Comis MD, chief clinical and medical research officer at OSE Immunotherapeutics, covers the company's lead immuno-oncology candidate, Tedopi. She outlines the current unmet...
► Artikel lesen
04.09.OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation147OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France - September 4, 2025, 6 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173...
► Artikel lesen
29.08.OSE Immunotherapeutics - Spotlight on OSE's diverse clinical pipeline317OSE Immunotherapeutics has made tangible progress across its clinical development pipeline, creating positive momentum, in our view. In immuno-inflammation, monoclonal antibody therapy lusvertikimab...
► Artikel lesen
29.08.OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM107OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN:...
► Artikel lesen
25.08.OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting2
20.08.OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer332NANTES, France, August 20, 2025 - 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins...
► Artikel lesen
16.07.OSE Immunotherapeutics: Half-Year Report on Liquidity Contract with Invest Securities2
25.06.OSE Immunotherapeutics provides an update on ongoing proceedings187OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing...
► Artikel lesen
20.06.OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules144OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN:...
► Artikel lesen
11.06.OSE Immunotherapeutics: ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 202510
05.06.OSE Immunotherapeutics - New UC biomarker underpins growth strategy412OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and immuno-oncology. In the inflammation space, the company revealed...
► Artikel lesen
04.06.Ose Immunotherapeutics: Documents made available to the shareholders for the combined general meeting of June 25th, 20253
04.06.OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology257OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab...
► Artikel lesen
03.06.OSE Immunotherapeutics - ASCO 2025 update showcases Tedopi potential379OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to Tedopi, its proprietary off-the-shelf neoepitope-based cancer...
► Artikel lesen
02.06.OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi in Pancreatic Cancer and Non-Small Cell Lung Cancer341OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1